Lipoprotein(a) Induces Human Aortic Valve Interstitial Cell Calcification
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Lipoprotein(a), or Lp(a), significantly increased alkaline phosphatase activity, release of phosphate, calcium deposition, hydroxyapatite, cell apoptosis, matrix vesicle formation, and phosphorylation of signal transduction proteins; increased expression of chondro-osteogenic mediators; and decreased SOX9 and matrix Gla protein (p < 0.001). Inhibition of MAPK38 and GSK3β significantly reduced Lp(a)-induced calcification of human aortic valve interstitial cells (p < 0.001). There was abundant presence of Lp(a) and E06 immunoreactivity in diseased human aortic valves. The present study demonstrates a causal effect for Lp(a) in aortic valve calcification and suggests that interfering with the Lp(a)pathway could provide a novel therapeutic approach in the management of this debilitating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644 · cited 1×
“Despite the similarities between aortic valve stenosis and coronary artery disease, both in terms of clinical risk factors and histopathological manifestations, statins do not have any effect on the progression of aortic valve stenosis (4,5), and it is increasingly evident that the pathogenesis of the 2 conditions is…”
Genetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008
Self-citationRajamannan, N. M., Evans, F. J., Aikawa, E., Grande-Allen, K. J., Demer, L. L., Heistad, D. D., Simmons, C. A., Masters, K. S., Mathieu, P., O'Brien, K. D., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.006767 · Cited by 842
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815 · cited 1×
“Despite the similarities between aortic valve stenosis and coronary artery disease, both in terms of clinical risk factors and histopathological manifestations, statins do not have any effect on the progression of aortic valve stenosis (4,5), and it is increasingly evident that the pathogenesis of the 2 conditions is…”
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595 · cited 1×
“Recently, a genome-wide association study in 3 large cohorts revealed that a single-nucleotide polymorphism in the apolipoprotein(a) (LPA) locus was significantly associated with the presence of aortic valve calcification (6,7).”
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.020 · Cited by 417
The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity
Tsimikas, S., & Witztum, J. L. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328308b622 · Cited by 138 · cited 1×
“The latter has long been recognized as a risk factor for cardiac disease, but its exact role in vivo has remained contentious (12).”
Fujisaka, T., Hoshiga, M., Hotchi, J., Takeda, Y., Jin, D., Takai, S., Hanafusa, T., & Ishizaka, N. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.10.055 · Cited by 55 · cited 1×
“Classically thought to result from degeneration of the aortic valve, a number of novel contributing mechanisms have been identified, including the role of mechanical stress, age-related changes in valvular cells and extracellular matrix, the regulation of calcium flux in both physiological and cardiovascular calcifica…”
Cited by
Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Zheng, K. H., Tsimikas, S., Pawade, T., Kroon, J., Jenkins, W. S. A., Doris, M. K., White, A. C., Timmers, N. K. L. M., Hjortnaes, J., Rogers, M. A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.070 · Cited by 343
Calcific aortic valve disease: mechanisms, prevention and treatment
Moncla, L.-H. M., Briend, M., Bossé, Y., & Mathieu, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00845-7 · Cited by 306
Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease
Boffa, M. B., & Koschinsky, M. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0153-2 · Cited by 284
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Lipoprotein(a) catabolism: a case of multiple receptors
McCormick, S. P. A., & Schneider, W. J. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.003 · Cited by 107
Metadata
- Authors
- Yu, B., Hafiane, A., Thanassoulis, G., Ott, L., Filwood, N., Cerruti, M., Gourgas, O., Shum-Tim, D., Al Kindi, H., de Varennes, B., Alsheikh-Ali, A., Genest, J., & Schwertani, A.
- Venue
- JACC: Basic to Translational Science
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 2
- Issue
- 4
- Pages
- 358-371
- ISSN
- 2452-302X (ISSN-L)
- OpenAlex
- W2747401552
- Cited by
- 96
- References
- 8
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.